Trial · NCT06351150
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
NCT06351150, Phase 3, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock. Trials, record NCT06351150. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06351150
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
- NCT number
- NCT06351150
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 214 participants, estimated
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Conditions
- Vasodilatory Shock
- Interventions
- Angiotensin II Injection, 0.9% sodium chloride injection
- First posted
- 2024-04-08
- Last updated
- 2025-01-23
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of subjects with blood pressure response at 3 hours after administration of study drug | 3 hours after dose | Defined as MAP ≥ 75 mmHg or MAP increase ≥ 10 mmHg from baseline compared to baseline without an increase in the dose of background vasoactive agents |
| Secondary | Sequential Organ Failure Assessment (SOFA) total score | 48 hours after dose | Change from baseline in Sequential Organ Failure Assessment (SOFA) total score. The SOFA score evaluates organ failure according to the conditions of respiratory, blood, liver, cardiovascular, central nervous, kidney and other systems, is scored from 0 to 4, with a higher score representing more severe failure. |
| Secondary | Cardiovascular SOFA subscore | 48 hours after dose | Change from baseline in Sequential Organ Failure Assessment (SOFA) subscore. The SOFA score evaluates organ failure according to the conditions of respiratory, blood, liver, cardiovascular, central nervous, kidney and other systems, is scored from 0 to 4, with a higher score representing more severe failure. |
| Secondary | Mortality at Day 7 | Day 7 after dose | All-cause mortality of subject at Day 7 |
| Secondary | Mortality at Day 28 | Day 28 after dose | All-cause mortality of subject at Day 28 |
| Secondary | Proportion of subjects with blood pressure response at 1 hour after administration | 1 hour after dose | Defined as MAP ≥ 75 mmHg or MAP increase ≥ 10 mmHg from baseline compared to baseline without an increase in the dose of background vasoactive agents |
| Secondary | Proportion of subjects with blood pressure response at 2 hours after administration | 2 hours after dose | Defined as MAP ≥ 75 mmHg or MAP increase ≥ 10 mmHg from baseline compared to baseline without an increase in the dose of background vasoactive agents |
| Secondary | Change in background vasoactive agent dose from 0 to 48 hours | 48 hours after dose | Change in background vasoactive dose from baseline to 48 hours after dose |
| Secondary | Absolute change in blood lactate from 0 to 3 hours | 3 hours after dose | Absolute change in blood lactate from 0 to 3 hours |
| Secondary | Absolute change in blood lactate from 3 to 48 hours | 3 to 48 hours after dose | Absolute change in blood lactate from 3 to 48 hours |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06351150
GET https://conductscience.org/api/trials/v1/NCT06351150/registered